Spots Global Cancer Trial Database for Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

Official Title: Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

Study ID: NCT04317651

Conditions

Non Small Cell Lung Cancer

Advanced Cancer

Metastatic Cancer

Interventions

Study Description

Brief Summary: This is a multicenter, observational, retrospective cohort study aimed at assessing the efficacy and safety of crizotinib in ALK positive NSCLC treated in real life setting.

Detailed Description: Primary efficacy objective: To assess the efficacy of crizotinib in real life setting Secondary objectives: 1. To evaluate the therapeutic response to crizotinib-based treatment 2. To identify additional biomarkers selectively present in the ALK positive population 3. To assess the safety of crizotinib (250 mg/bid) in the treatment of NSCLC in real life setting Non-small-cell Lung Cancer (NSCLC) remains the leading cause of cancer death in Western Countries. Identification of anaplastic lymphoma kinase (ALK) gene rearrangements reinforced the role of targeted therapies in lung cancer. The EML4-ALK fusion gene is detected in 3-7% of patients with adenocarcinomas of the lung and is associated with specific clinical pathological features, including young age, absent or minimal smoking history and adenocarcinoma histology. However, such clinical features do not properly select patients for ALK inhibitors (ALK-Is) and, consequently, molecular testing is mandatory. Indeed, current guidelines recommend to test ALK rearrangements at diagnosis all patients with advanced lung adenocarcinoma, due to immediate therapeutic implications.